ALLOSOURCE® ANNOUNCES RESEARCH FEATURING ITS PROPRIETARY VIATRUE® CRYOPRESERVATION PROCESS IS BEING PRESENTED AT THE 18TH INTERNATIONAL CARTILAGE REGENERATION & JOINT PRESERVATION SOCIETY WORLD CONGRESS

CENTENNIAL, Colo., Oct. 10, 2025 /PRNewswire/ -- AlloSource^®, a U.S.-based life sciences organization that helps restore patient functionality by transforming the gift of human tissue donation into enhanced medical products, announced research featuring its proprietary ViaTrue^® Cryopreservation Process is being presented at the 18th International Cartilage Regeneration & Joint Preservation Society (ICRS) World Congress. The research demonstrates positive clinical and scientific results for two of AlloSource's cartilage allografts. 

ViaTrue is AlloSource's innovative, proprietary cryopreservation technology, which includes a controlled rate freezing of fresh cartilage within 72 hours of donor death, when the chondrocytes are still highly viable. ViaTrue processed cartilage products are then preserved for up to two years, maintaining high chondrocyte viability.

The first poster titled, "5-Year Outcomes After Cryopreserved Osteochondral Allograft: Interim Analysis of IKDC and KOOS Scores in Knee Cartilage Repair" evaluates the prospective clinical outcomes of patients who received ProChondrix^® CR Osteochondral Allograft in focal cartilage lesions of the patella and femoral condyle of the knee. ProChondrix CR is a is a single-stage, cryopreserved, articular cartilage allograft. Significant improvements were revealed in all patient-reported outcome scores, up to 60 months, suggesting ProChondrix^® CR is a viable approach to improving long-term quality of life and joint functions in patients with focal cartilage damage. The study has patients that have not met the 60-month timeline, so additional outcomes are pending.

"Cryopreserving allografts with ViaTrue helps to alleviate inventory management challenges and provides surgeons with more flexibility for their patients," said Carolyn Rorick, AlloSource Senior Director Product Development, Innovation and Clinical Research. "Showing the positive patient outcomes from this ongoing evaluation is an important step in proving the impact cryopreserved cartilage can have on healing patients."

The second poster, featuring research by Colorado State University in Fort Collins, Colorado titled "Cryopreservation Vs Fresh Osteochondral Allografts: Is There a Difference?" evaluates histologic and biomechanical properties of fresh versus cryopreserved OCAs (up to one year). The data showed no significant difference between allografts regardless of storage conditions, indicating that cryopreservation is a promising alternative to current fresh grafting practices. The extended shelf-life of cryopreserved allografts could help alleviate logistical and accessibility challenges of fresh OCA transplantation.

"There is still research to do in the body to show that cryopreserved osteochondral allografts are as good as fresh allografts, but this work is the first step towards proving that cryopreserved grafts can be a viable option for the millions of patients that need them," said Dr. Laurie Goodrich, Director of the Orthopaedic Research Center at Colorado State University's C. Wayne McIlwraith Translational Medicine Institute.

The ICRS bring together scientists, researchers, clinicians and industry and are the main forum for collaboration in cartilaginous tissue research that recognizes the need for research in the continuum from cartilage injury to degenerative joint disease. For additional details on research featuring AlloSource's proprietary ViaTrue^® Cryopreservation Process visit the ProChondrix CR E-Poster online #208 and the comparison of fresh and cryopreserved osteochondral allograft cores E-Poster online #011. Also, visit the AlloSource team at ICRS at booth #31.

About AlloSource
AlloSource, a life sciences organization, helps restore patient functionality by transforming the gift of human tissue donation into enhanced medical products that enable a life of movement, health, and wellbeing. The organization partners with medical professionals and biomedical companies who share our drive for innovation and quality in the use of human tissue allografts for medical advancements. Headquartered in Centennial, Colorado, AlloSource has served a global marketplace since 1994. Learn more at allosource.org.

Media Contact
Cindy Mason
AlloSource
720. 873. 0213
[email protected]

SOURCE AlloSource